Key points are not available for this paper at this time.
Background: PSCA, a cell surface protein, is upregulated in many solid tumors Day 7). Eligibility criteria include previously treated metastatic pancreatic cancer (mPDAC) with measurable disease 2 had cell persistence >3 weeks; all had elevated serum cytokines (IP-10, TNFα) correlated with cell expansion. Best response after ≥1 scan was 4 SD ≥ 8 weeks with 2 minor responses (not confirmed; 1 patient had matched CA19-9 decrease) Consulted: SOBI, Ipsen, Takeda, Bayer, Heron, Agenus; Speakers' bureau: Taiho Pharmaceutical, BMS, Merck Serono, Celgene. S. Paulson: Stock: Immunomedics, Juno, Alexion, Actinium; Consulted: Ipsen, Eisai, AAA, BMS, Merrimack, Taiho; Research funding: Taiho, Eli Lilly, AstraZeneca. G.A. Manji: Consultant: Ardelyx; Research funding: Plexxikon. O. Gardner: Employee of Bellicum Pharmaceuticals. A. Malankar, J. Shaw, D. Blass, B. Ballard, M. Anumula, A. Foster, J. Senesac, P. Woodard: Employee and stock owner: Bellicum Pharmaceuticals. X. Yi: Employee of Bellicum Pharmaceuticals. All other authors have declared no conflicts of interest.
Becerra et al. (Sat,) studied this question.